INTRODUCTION

Ion channels in drug research and discovery
Ion channels are a large and diverse family of transmembrane pore-forming proteins present in a large variety of cell types. They facilitate the rapid passive transport of specific inorganic ions through the plasma and organelle membranes.
Ion channels regulate a variety of physiological processes. Because of their pivotal role, ion channel dysfunction has adverse effects on physiology, and could lead to many severe chronic multi-well configurations either in a plate-based or chip-based format to enable higher throughput screening, currently this technology is used in the majority of automated systems.
Aims
Aim of the present work was to investigate the role of automated patch-clamp technique in drug research and development and compare it with the conventional cellular electrophysiological techniques. The two main scopes of our studies were:
1. To determine the value of results of screening processes obtained with automated patch-clamp methods using cell lines stably expressing ion channels. During this phase of work the main goals were to evaluate the usability of the studied automated patch-clamp equipment in different screening projects and to analyse the utility of the studied system with comparing the effect of the active compounds in cell lines used for screening and in native targets measured by the conventional electrophysiological methods.
2.
To analyze the value of safety pharmacology data obtained with automated patchclamp methods. During this phase of work the main goal was to evaluate the practical usability and the biological significance of the results obtained with the studied automated patch-clamp equipment in stable cell lines.
MATERIALS AND METHODS
Conventional microelectrode technique
New Zealand rabbits of either sex weighing 1-2 kg or adult mongrel dogs (8-14 kg) of either sex were used. Isolated muscle preparations obtained from the right ventricle were individually mounted in a tissue chamber with the volume of 50 ml. Each preparation was initially stimulated through a pair of platinum electrodes in contact with the preparation using rectangular current pulses of 2 ms duration. Transmembrane potentials were recorded at 37°C using conventional glass microelectrodes, filled with 3 M KCl and having tip resistances of 5-20 MΩ, connected to the input of a high impedance electrometer (Experimetria, type 309) which was coupled to a dual beam oscilloscope.
Manual patch-clamp method
Ventricular myocytes were enzymatically dissociated from hearts of New Zealand rabbits of either sex weighting 1-2 kg using the segment perfusion technique. Patch-clamp micropipettes were fabricated from borosilicate glass capillaries (Harvard Apparatus) using a micropipette puller (Flaming/Brown, type P-97). These electrodes had resistances between 1.5 and 2.5 MΩ when filled with pipette solution. Membrane currents were recorded at 37°C with Axopatch
The EC 50 of GABA was determined to 32.20 ± 1.85 µM from the Hill plot. The effect of the GABA A channel antagonist bicuculline was investigated on GABA A current. The estimated IC 50 value was 371.06 ± 3.43 nM.
HEK-HCN cell lines:
The blocking action of ivabradine on HCN1 and HCN4 channels expressed in HEK cells was investigated. Ivabradine reduced both currents in 10 μM concentration by 64.52 ± 5.36% and 63.79 ± 1.07%, respectively.
HEK-GIRK1/4 cell line: Six compounds were studied on HEK-GIRK cells. These experiments were performed at room temperature and results grounded for the screening project performed (see Section 3.2.) also at room temperature. The IC 50 of chloroquine, desipramine, JTV-519, NIP-142, propafenone and quinidine were 463.70 ± 34.61 nM, 1.47 ± 0.17 μM, 814.24 ± 109.34 nM, 175.75 ± 8.59 nM, 372.99 ± 27.69 nM and 5.04 ± 0.62 μM, respectively. Effect of the antiarrhythmic drug amiodarone and its main metabolite formed during chronic treatment (desethylamiodarone, DEA) was also investigated. These studies were performed as parts of the cardiac electrophysiological investigation of these compounds and were performed at 37°C. The IC 50 values determined by the Patchliner were nearly identical (1.77 ± 0.18 and 1.82 ± 0.15 μM, respectively).
CHO-Kv1.4 cell line:
The blocking effects of chromanol 293B and 4-aminopyridine on Kv1.4 ion channel were investigated at room temperature. Estimated IC 50 values of these compounds found to be 85.69 ± 8.38 μM and 791.33 ± 26.84 μM, respectively.
HEK-hERG cell line:
Two compounds, dofetilide and sotalol were tested in hERG assay with automated patch-clamp system. Results are shown in Section 3.3.1.
Screening projects: Investigation of ion channel modulator capability of compounds with automated patch-clamp equipment
The characterized cell lines were used in screening and safety pharmacology projects performed with the Patchliner. All screening projects were carried out at room temperature.
Screening of preselected chemical libraries on GIRK channel
In order to find agents for the treatment of atrial fibrillation, screening of preselected chemical libraries was performed on GIRK channel expressing cell line. During our screening project a set of 868 compounds was tested. Compounds were screened in two concentrations (1 and 10 μM). Approximately 13% of the preselected compounds showed a notable (i.e. at least 50% decrease in the GIRK current at 10 μM concentration) blocking effect. Compounds were ranked according to their GIRK inhibitory effect. Eleven compounds were chosen from the group of most effective molecules upon their blocking effect and chemical structure. The dose-response curves of these compounds were determined in detailed experiments.
Substrates were chosen for selectivity studies by the more precise results of these later studies: hERG inhibitory properties of 4 compounds with the most intense GIRK blocking effect values under 0.5 μM) were investigated on HEK-hERG cells in 6 concentrations. One out of the 4 chosen compounds showed similar blocking activity on both GIRK and hERG channels: IC 50 values of Ryt-243 were 100.14 ± 5.10 nM and 47.56 ± 5.31 nM, respectively. The other 3 compounds showed an at least 10 times higher blocking activity on GIRK channels compared to the results obtained on hERG channel (IC 50 values on GIRK and hERG channels were 281.29 ± 9.48 nM and 2.91 ± 0.29 μM for Ryt-144, 335.30 ± 23.81 nM and 8.05 ± 0.89 μM for 495.43 ± 15 .90 nM and 9.16 ± 1.30 μM for Ryt-230). As hERG blocking effect can be even useful in antiarrhythmic treatment Ryt-243 was subjected to further investigation: despite of its hERG blocking effect the compound lengthened the action potential in rabbit ventricular muscle neither in 5 µM nor in 10 µM concentrations. was also studied in dog model of chronic atrial fibrillation. The compound had a strong antiarrhythmic effect in this investigational set-up: the incidence of atrial fibrillation was reduced by 65-70% by both 0.3 mg/kg and 1 mg/kg doses. Based on these antiarrhythmic results a patent was filed in which anti-atrial fibrillation effects of Ryt-243 are chartered.
Compounds showing GIRK-selectivity are also subjected to further investigation including antiarrhythmic effect evaluation and structure-effect analysis.
Screening of different substrates originated from plants on GIRK channel
Screening of natural plant compounds on GIRK channel
Compounds originated from natural sources were also investigated in our GIRK screen project. During this phase of screening project a set of 281 natural plant compounds was tested. These molecules were chosen randomly and were not selected. Compounds were screened also in two concentrations (1 and 10 μM). Approximately 9% of the investigated natural compounds showed a notable (i.e. at least 50% decrease in the GIRK current at 10 μM concentration) blocking effect. The 26 most effective molecules were selected for further evaluation following the primary screen. These compounds were also tested on Kv1.4 and hERG cell lines and selectivity of their GIRK blocking effect was evaluated with these experiments. Six natural plant compounds (Ryt-963, Ryt-964, Ryt-1009 , Ryt-1103 , Ryt-1187 and Ryt-1194) were chosen from the group of most effective ones upon their blocking effects and chemical structure. The dose-response curves of these 6 molecules were determined in detailed experiments. IC 50 values on GIRK current were 524.25 ± 35.87 nM for Ryt-963, 2.25 ± 0.33 μM for Ryt-1009, 3.66 ± 0.30 μM for Ryt-964, 5.33 ± 0.23 μM for Ryt-1194, 9.68 ± 0.27 μM for Ryt-1187 and 12.20 ± 0.31 μM for Ryt-1103.
Screening of plant extracts on GIRK channel
Testing a new way of tracing biologically active compounds extracts of Polygonum persicaria were also investigated in our GIRK screen system, with the aim to identify natural sources of promising ion channel blocking compounds. For this purpose hexane, chloroform, methanol and aqueous extracts were prepared from the dried whole plant. Extracts of different polarity were investigated at two concentrations (0.01 mg/l and 0.1 mg/l). The chloroform extract exhibited considerable GIRK channel inhibitory activity. This extract was fractionated by vacuum liquid chromatography resulting six fractions (fractions 1-6), which were also evaluated for GIRK modulation activity. The most active fractions (fraction 4 and 5) were subjected then to RP-HPLC, affording the isolation of the main compounds 1-4 in pure form.
The eluates containing the mixture of other (minor) compounds were also collected during the HPLC chromatography. Interestingly, either separated or combined application of the isolated main compounds of the active fractions (compound 1-4) possess only very moderate activity on GIRK channel, while the HPLC eluates of fraction 4 and 5 containing a mixture of minor compounds revealed to be active, indicating the presence of electrophysiologically active agents among the minor compounds. Further studies are on the way in order to identify the minor compounds responsible for the GIRK blocking effect. Nevertheless our studies confirm the usability of the applied method of tracing active compounds upon their biological activity.
Safety pharmacology studies
Assessment of hERG assay performed with automated patch-clamp system in the safety evaluation of investigational compounds
Two compounds (dofetilide and sotalol) were tested in hERG assay both at room temperature and at 37°C with automated patch-clamp system. The IC 50 values of dofetilide were very similar (8.41 ± 0.19 nM at room temperature and 7.29 ± 0.16 nM at 37°C). Sotalol displayed different properties at room temperature versus physiological temperature (37°C). Sotalol blocked hERG channels at room temperature with an IC 50 of 773.74 ± 9.28 μM. However, at 37°C sotalol was more potent (IC 50 = 342.84 ± 24.82 μM). To evaluate the prognostic value of hERG assay these compounds were subjected for further investigations. The I Kr current blocking capability of the compounds was tested on rabbit ventricular muscle with manual patch-clamp method. The IC 50 values of dofetilide and sotalol were 13.02 ± 2.56 nM and 51.60 ± 9.82 μM, respectively. IC 50 values obtained in hERG and I Kr assays showed a good correlation in case of dofetilide while IC 50 value obtained from I Kr measurements was approximately 7 times lower in case of sotalol. To study the safety pharmacology consequences of the hERG and I Kr inhibitory effect of dofetilide and sotalol the effect of these compounds on action potential configuration were studied in rabbit right ventricular muscle preparations. The prolongation of APD 90 was 47.8 ± 12.9 % in case of 13 nM dofetilide while 52 μM sotalol extended the action potential duration with 56.0 ± 4.6 % (n = 5).
Effects of Chelidonium majus extracts and major alkaloids on hERG ion channel and on dog cardiac action potential
Chelidonium majus or greater celandine is spread throughout the world, and it is an important plant of the modern phytotherapy, used not only externally, but also internally. Safety pharmacology properties of this plant are not widely clarified. Therefore, effects of C. majus herb extracts and alkaloids on hERG K + current and on cardiac action potential were studied.
For the investigations of hERG blocking effects of C. majus, 25% and 45% ethanol extracts were prepared. Both extracts revealed significant hERG ion channel inhibitory activity at room temperature with estimated IC 50 values of 8.31 ± 0.79 μg/ml and 5.09 ± 0.49 μg/ml.
The hERG blocking potencies of the major alkaloids of the plant (sanguinarine, chelidonine, berberine and coptisine) were also evaluated and found that all alkaloids showed considerable inhibitory effect apart from coptisine. Sanguinarine and chelidonine were to have the highest inhibitory effect with the IC 50 value of 0.88 ± 0.08 µM and 1.00 ± 0.10 µM, respectively. The hERG channel modulatory activity of berberine could be characterized by the IC 50 value of 6.46 ± 0.54 µM, whereas coptisine exhibited only marginal effect (IC 50 = 90.08 ± 2.88 µM).
To investigate the safety pharmacology consequences of the hERG blocking effect of C. majus extracts and alkaloids the effect of these agents -with the exception of coptisine -on action potential configuration were studied in canine right ventricular muscle preparations.
Both extracts moderately extended the action potential duration at 5 μg/ml concentration in statistically significant manner at basic stimulation cycle length of 1000 ms. The prolongation of APD 90 was 10.5% in case of the 25% ethanol extract while the 45% ethanol extract lengthened the action potential duration with 6.7%. The effects of berberine, chelidonine and sanguinarine on the action potential parameters at concentrations of 1 µM and 10 µM were also investigated in dog ventricular muscle at constant cycle length of 1000 ms. All compounds showed mild but statistically significant effect on APD 90 (4.6%, 6.1% and 6.3%
prolongation, respectively) at 1 μM concentration. At 10 μM concentration the action potential prolongation was more considerable (18.4%, 18.3% and 16.0%). Compounds originated from natural sources were also investigated in GIRK screen project.
DISCUSSION
These natural plant compounds were chosen randomly and were not preselected. Our results reflect the high hit rate of the natural compounds. Testing a new way of tracing biologically active compounds extracts of Polygonum persicaria were also investigated in our GIRK screen system, with the aim to identify natural sources of promising ion channel blocking compounds. To the best of our knowledge, GIRK inhibitory assay was used for the first time for screening plant extracts for potassium ion channel blockers. In this study the GIRK channel inhibitory activity of the chloroform extract of Polygonum persicaria was demonstrated, and new natural flavonoids were identified from the extract. Unfortunately, the isolated compounds have only moderate activities on GIRK channel; therefore further studies are needed in order to identify minor compounds responsible for the potassium ion channel modulatory activity.
Kv1.4 is important in the regulation of the fast repolarizing phase of action potentials in heart and thus may influence the duration of cardiac action potential. This cell line had relatively high currents in the nanoamper range. Both tested reference compound (chromanol 293B and 4-aminopyridine) blocked the current. All these data are in good agreement with literature data in myocytes. Based on our results, several natural plant compounds were selected for further evaluation following the primary screen on GIRK channel. These agents were also tested on Kv1.4 cell line and selectivity of their GIRK blocking effect was evaluated with these experiments.
Besides the ion channel drug screening to discover and develop new and more effective drugs, another important aspect of the application of automated patch-clamp systems is the safety pharmacology. Life threatening cardiac arrhythmias and sudden cardiac death caused by drugs are one of the major safety issues for pharmaceutical industry and regulatory agencies. Based on these experiences, safety pharmacology studies of Chelidonium majus were achieved, where the effects of extracts and alkaloids of the plant were investigated on hERG current as well as on ventricular action potential. In our electrophysiological study we investigated C. majus herb hydroalcoholic extracts and its alkaloids. The examined substances not only inhibit the hERG current, but also extend the duration of the action potential. In 
3.
Compounds originated from natural (plant) sources were also involved in GIRK screen project. Our studies reflect the outstandingly high hit rate of compounds originated from natural sources.
4.
To the best of our knowledge, GIRK inhibitory assay was used for the first time for screening of plant extracts for inhibitors, with the aim to identify natural sources of promising ion channel blocking compounds.
5.
In safety pharmacology studies, we showed important and not well understood differences between the hERG-blocking ability of different compounds evaluated with automated patch-clamp method or other techniques such as I Kr experiments with manual patch-clamp or action potential studies. We demonstrated that the estimation of proarrhytmic liability by hERG assays is not as adequate as it was previously thought and can be handled only with precaution.
6.
Our electrophysiological studies on extracts and alkaloids of Chelidonium majus herb revealed that the plant possess hERG channel inhibition and prolong the duration of cardiac action potential. These results may contribute to the understanding of the toxic effects of C. majus and highlight the potential cardiac risk of the usage of this herb. Finally, I acknowledge the financial support of the Richter Gedeon Talentum Foundation and the continuous technical assistance of the Nanion Technologies GmbH.
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